Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Quint-Fonsegrives – page 59

1 508 clinical trials in Quint-Fonsegrives, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Quint-Fonsegrives at a glance
1 508
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 508 trials in Quint-Fonsegrives

Open in trial search

Osteomyelitis

Not yet recruiting

Zoledronic acid versus placebo for pain relief in children with chronic recurrent multifocal osteomyelitis resistant to NSAIDs

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Zoledronic Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer+2

Not yet recruiting

Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Unicancer

Infectious pleural effusion

Not yet recruiting

Early Saline Pleural Irrigation for Patients with Complicated Pleural Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Acute myeloid leukaemia

Not yet recruiting

Venetoclax Added to Standard Chemotherapy and Midostaurin for Patients with FLT3-Mutated Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Abortion threatened

Not yet recruiting

Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Amoxicillin
  • Sponsor:Assistance Publique Hopitaux De Paris

Craniopharyngioma

Not yet recruiting

A study to evaluate the effectiveness of semaglutide for treating obesity caused by craniopharyngioma in children aged 12 to 17 years.

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Vamifeport trihydrochloride
  • Sponsor:CSL Behring LLC

Mechanical ventilation

Not yet recruiting

Study of ketamine hydrochloride to improve recovery in adults requiring unplanned mechanical ventilation in the intensive care unit

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

B-cell lymphoma+1

Not yet recruiting

Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Quint-Fonsegrives

What the registry says about research in the country

01 Urological Research

Extensive research focusing on bladder cancer treatments, including innovative therapies for both muscle-invasive and non-muscle-invasive cases. Studies also address prostate conditions, from benign hyperplasia to advanced cancer.

  • Advanced bladder cancer treatments
  • Prostate cancer therapy optimization
  • Kidney stone management

Novel approaches combine immunotherapy with targeted treatments to improve patient outcomes.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on triple-negative and hormone receptor-positive variants. Studies evaluate new approaches in colon cancer management using circulating tumor DNA analysis.

  • Triple-negative breast cancer therapy
  • Colorectal cancer treatment
  • Lung cancer interventions

Investigations combine immunotherapy with traditional treatments for enhanced efficacy.

03 Specialized Medicine

Research addressing pulmonary conditions and specialized medical needs. Studies include evaluation of treatments for chronic obstructive pulmonary disease and migraine management in emergency settings.

  • COPD treatment optimization
  • Migraine therapy
  • Diabetic eye conditions

Focus on improving patient quality of life through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.